Effect of Rosiglitazone

This study has been completed.

Sponsored by:	University Hospital, Montpellier
Information provided by:	University Hospital, Montpellier
ClinicalTrials.gov Identifier:	NCT00285142

Purpose

To evaluate :

Condition	Intervention
Healthy	Drug: rosiglitazone

Drug Information available for: Insulin Rosiglitazone Rosiglitazone Maleate

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Pharmacodynamics Study
Official Title:	Assessment of the Effect of Rosiglitazone on Insulin Secretion in Healthy Volunteers

Further study details as provided by University Hospital, Montpellier:

Primary Outcome Measures:

insulin response and insulin sensitivity assessed by 2-hours 10 mmol/l hyperglycemic clamp, started 45 min after treatment intake

Secondary Outcome Measures:

Estimated Enrollment:	12
Study Start Date:	June 2004
Estimated Study Completion Date:	November 2004

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00285142

Locations

France
Centre d'Investigation Clinique
Montpellier, France, 34295, cedex 5

Sponsors and Collaborators

University Hospital, Montpellier

Investigators

Principal Investigator:

PIERRE PETIT, MD-PhD

Centre d'Investigation Clinique

More Information

Publications indexed to this study:

Study ID Numbers:	UF7715
Study First Received:	January 31, 2006
Last Updated:	October 5, 2006
ClinicalTrials.gov Identifier:	NCT00285142
Health Authority:	France: Afssaps - French Health Products Safety Agency

Keywords provided by University Hospital, Montpellier:

rosiglitazone
insulin secretion
clinical trial
healthy
persons

Study placed in the following topic categories:

Healthy
Rosiglitazone
Insulin

Additional relevant MeSH terms:

Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009